A proteasome is a large molecular complex that breaks down proteins into short peptides through the controlled cleavage of peptide bonds. Proteasomes occur in all eukaryotes and archaea, as well as in some bacteria. In eukaryotic cells, they are found principally in the cytoplasm and nucleus. Their functions include removing damaged or misfolded proteins, regulating the abundance of short-lived regulatory proteins, and producing peptides for immune recognition. The best-characterized form is the 26S proteasome, which combines a protein-degrading core with regulatory machinery that recognizes substrates and uses energy to unfold them.
Structure and organization
The 20S core particle
The proteolytic component is the 20S core particle, a barrel-shaped assembly of 28 protein subunits arranged in four stacked rings. Each ring contains seven subunits, giving the arrangement . The two outer rings consist of alpha subunits, while the two inner rings consist of beta subunits.
The alpha rings form gated entrances to the internal chamber. The beta rings contain the catalytic sites, which face inward. This arrangement confines protein cleavage to an enclosed space and helps prevent uncontrolled digestion of cellular proteins.
In the standard eukaryotic core, three distinct beta-subunit types in each beta ring are catalytically active:
- β1, associated with preferential cleavage after acidic residues.
- β2, associated with preferential cleavage after basic residues.
- β5, associated with preferential cleavage after hydrophobic residues.
These activities are conventionally called caspase-like, trypsin-like, and chymotrypsin-like, respectively. The names describe substrate preferences rather than close structural relationships to those enzymes. Cleavage specificity is not absolute and depends on the surrounding protein sequence.
Proteasomal active sites use the amino-terminal threonine of a mature beta subunit for catalysis. The core is therefore classified as an N-terminal threonine protease.
The 19S regulatory particle and 26S proteasome
The 20S core can associate with a 19S regulatory particle at one end or at both ends. These assemblies are commonly grouped under the term 26S proteasome, although the doubly capped form is also called the 30S proteasome. The designations 20S, 19S, and 26S refer to sedimentation behavior, not additive molecular masses or subunit counts.
The 19S particle contains:
- Receptors that recognize proteins marked for degradation.
- Enzymes that remove the degradation marker.
- A ring of six ATPase subunits that unfolds proteins and moves them into the core.
- Additional subunits that organize and regulate these activities.
The ATPase ring converts energy from adenosine triphosphate into mechanical work. Because the core entrance is narrow, most folded proteins must be unfolded before they can enter.
Substrate selection and degradation
Ubiquitin-dependent targeting
Many proteins destined for proteasomal degradation are marked with ubiquitin, a small protein that can be covalently attached to other proteins. Ubiquitin attachment generally involves three classes of enzymes:
- E1 ubiquitin-activating enzymes, which activate ubiquitin using ATP.
- E2 ubiquitin-conjugating enzymes, which carry activated ubiquitin.
- E3 ubiquitin ligases, which provide much of the specificity for selecting target proteins.
Repeated ubiquitin attachment can create a polyubiquitin chain. Chains linked through ubiquitin lysine 48 are a well-established degradation signal, but other chain architectures can also support proteasomal targeting. Not every ubiquitin modification directs degradation: ubiquitin also participates in signaling, transport, and DNA repair.
A suitable ubiquitin signal is often insufficient by itself. Efficient degradation commonly also requires an accessible, relatively unstructured segment of the substrate that the proteasome can engage. Substrate selection therefore depends on both the targeting signal and the physical properties of the protein.
Processing by the proteasome
After a substrate binds, proteasome-associated deubiquitinating enzymes remove or remodel its ubiquitin chain. Ubiquitin can then be reused. The ATPase motor engages an initiation region, unfolds the substrate, and translocates it through the opened gate into the core.
Within the central chamber, repeated hydrolysis of peptide bonds generates short peptides. These products leave the proteasome and may be further degraded by other enzymes into amino acids, which can re-enter cellular metabolism.
ATP is required for ubiquitin activation and for the mechanical processing of many substrates. Peptide-bond cleavage in the catalytic chamber does not itself directly consume ATP.
Ubiquitin-independent degradation
Not all proteasomal degradation requires ubiquitin. Some proteins are delivered to the 26S proteasome through alternative recognition mechanisms. The 20S core can also degrade certain unfolded, intrinsically disordered, or oxidatively damaged proteins without the 19S particle and without ATP-dependent unfolding.
These pathways complement rather than replace ubiquitin-dependent degradation. Their contributions vary with substrate structure, cell type, and physiological conditions.
Cellular functions
Protein quality control
Proteasomes help maintain the balance between protein production, folding, and removal. Misfolded or damaged proteins can expose normally buried regions and acquire degradation signals. Their clearance limits the accumulation of potentially harmful protein species.
Proteasomal quality control also operates on proteins associated with the endoplasmic reticulum. In endoplasmic-reticulum-associated degradation, selected defective proteins are extracted or moved into the cytosol, ubiquitinated, and degraded.
The proteasome is not the cell’s only protein-disposal system. Lysosomes and autophagy provide complementary routes, particularly for material such as large aggregates and damaged organelles that cannot pass through the proteasome’s narrow entrance. The division of labor between these systems is not absolute, and their activities are coordinated.
Regulation of protein abundance
Proteasomal degradation is selective and can be tightly timed. It regulates proteins involved in the cell cycle, gene expression, signaling, and apoptosis.
For example, the destruction of cyclins and other cell-cycle regulators helps make transitions between cell-cycle stages directional. Degradation can also terminate a signaling response by removing an activated regulator, or initiate one by removing an inhibitory protein.
In some cases, proteasomes carry out limited processing rather than complete destruction, releasing a functional protein fragment.
Antigen processing
Proteasomes generate many of the peptides displayed by major histocompatibility complex class I molecules. After further transport and, where needed, trimming, these peptides are presented at the cell surface for inspection by T cells.
This pathway allows the immune system to monitor proteins produced inside cells, including proteins derived from viruses. Proteasomal cleavage influences which peptides become available for presentation, although transport, trimming, and binding to class I molecules also determine the final peptide repertoire.
Specialized forms and regulators
Immunoproteasomes
In vertebrates, alternative catalytic beta subunits can replace the standard β1, β2, and β5 subunits during core assembly. The resulting immunoproteasome contains β1i, β2i, and β5i, also known as LMP2, MECL-1, and LMP7.
Immunoproteasomes are abundant in several immune-cell populations, and their production can be induced in other cells by interferons, particularly interferon-gamma. Their altered cleavage preferences change the repertoire of peptides available for antigen presentation. They also participate in protein homeostasis during inflammatory responses.
Thymoproteasomes
Thymoproteasomes are specialized proteasomes found in cortical thymic epithelial cells. They contain the distinctive catalytic subunit β5t together with β1i and β2i. The peptides they generate contribute to the positive selection of developing CD8 T cells and the establishment of central immune tolerance.
Alternative regulatory particles
The 20S core can bind regulators other than the 19S particle. These include PA28, also called the 11S regulator, and PA200. Such regulators influence gate opening and substrate processing but do not provide the same ubiquitin-recognition and ATP-driven unfolding machinery as the 19S particle.
Hybrid proteasomes can carry different regulators at opposite ends of the core. Proteasomes therefore constitute a family of related assemblies rather than a single invariant complex.
Evolution and discovery
Archaeal proteasomes often have simpler subunit compositions than eukaryotic proteasomes, while retaining the four-ring core architecture. Some bacteria, including mycobacteria, also possess proteasomes. Many other bacteria instead rely on distinct ATP-dependent proteases. The mycobacterial proteasome can receive proteins marked by Pup, a protein modifier unrelated in sequence and structure to ubiquitin.
The modern understanding of proteasomal degradation emerged from studies of ATP-dependent protein breakdown and the ubiquitin system during the 1970s and 1980s, alongside biochemical characterization of large intracellular protease complexes. Structural studies later established how the barrel-shaped core and regulatory particles perform selective degradation.
The 2004 Nobel Prize in Chemistry was awarded to Aaron Ciechanover, Avram Hershko, and Irwin Rose for the discovery of ubiquitin-mediated protein degradation.
Research and medical relevance
Proteasome structure and function are studied using biochemical reconstitution, genetic approaches, X-ray crystallography, and cryo-electron microscopy. These methods have revealed multiple conformational states associated with substrate recognition, unfolding, translocation, and gate opening.
Experimental assays require careful interpretation. Cleavage of a small fluorescent peptide measures aspects of catalytic activity, but it does not reproduce all the steps required to recognize and destroy a folded, ubiquitinated protein. Core-particle activity, intact 26S activity, and overall cellular protein turnover are therefore related but distinct measurements.
Proteasomes are established drug targets in cancer treatment. Bortezomib, carfilzomib, and ixazomib inhibit proteasomal catalytic activity and are used in the treatment of multiple myeloma; some also have other approved indications. Their clinical effects reflect disruption of protein homeostasis and regulatory pathways. Because proteasomes also perform essential functions in healthy cells, inhibition can cause substantial adverse effects.
Proteasomal dysfunction is also investigated in aging and neurodegenerative disease. Relationships among impaired degradation, protein aggregation, and cellular injury can be reciprocal, so an observed change in proteasome activity does not by itself establish whether it is a cause or a consequence of disease.